Grifols, S.A.

NASDAQ:GRFS

Drug Manufacturers - General

Healthcare
$8.47 +0.34%

+$0.03 today

Market cap
$7.17B
Beta
1.17
P/E (TTM)
14.7
EPS (TTM)
$0.61
Dividend yield
1.67%
52W Low $7.26High $11.14

Volume 0.59M

Average 0.69M

GRFS Total Non-current Liabilities

All obligations due after more than one year.

Grifols, S.A.NASDAQ: GRFS

Total Non-current Liabilities · Q2 FY2026 · quarter ended Jun 2026

Total non-current liabilities falls 3.0% from a year ago

Total non-current liabilities stood at €9.87B at the end of Q2 FY2026, down 3.0% from a year earlier and down 2.4% from the prior quarter. Over 3 fiscal years it compounded at -3.4% a year.

Context

  • Total non-current liabilities amounted to 49.1% of total assets at the end of Q2 FY2026, down 2.3 pp from a year earlier.
  • Total non-current liabilities increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether total non-current liabilities keeps falling in the next quarterly balance sheet after a -3.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
€9.87B-2.4% QoQ
Last fiscal yearDec 2025
€10.12B-4.9% YoY
Year agoJun 2025
€10.18B-3.0% since
Total Non-current Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-3.0%——
1 year-4.9%——
3-year CAGR-3.4%——
5-year CAGR——
10-year CAGR——

Total Non-current Liabilities history

EUR · from the balance sheet

Latest · FY2025
10.12B EUR
Year-over-year change
-4.9%
4-year CAGR
+4.6%

Total Non-current Liabilities vs competitors

How GRFS compares with its peers on the latest reported figures

  • Peers report in different currencies, so total non-current liabilities is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -3.0% is the 5th highest of 9, against a peer median of -0.0%.
  • Total non-current liabilities amounts to 49.1% of total assets for GRFS, versus a peer median of 32.7%.
GRFS Competitors
Total Non-current Liabilities for GRFS and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ABTAbbott LaboratoriesJun 2026$39.64B USD+100.9%-7.5%36.3%
BDXBecton, Dickinson and CompanySep 2026$15.62B USD-27.8%-8.4%30.8%
GRFSGrifols, S.A.Jun 2026€9.87B EUR-3.0%-3.4%49.1%
QDELQuidelOrtho CorporationMar 2026$2.81B USD+16.5%-0.4%50.0%
BIOBio-Rad Laboratories, Inc.Jun 2026$2.12B USD-16.5%-7.7%20.6%
HAEHaemonetics CorporationJun 2026$1.27B USD+20.7%+15.0%53.5%
MRVIMaravai LifeSciences Holdings, Inc.Jun 2026$209.74M USD-41.6%-34.7%34.7%
ADMAADMA Biologics, Inc.Jun 2026$200.25M USD+135.3%-21.0%29.3%
TECHBio-Techne CorporationSep 2026$109.86M USD-73.6%-9.2%4.2%
Peer median (excluding GRFS) —-0.0%-8.1%32.7%

Competitors are the stored peer set for GRFS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents655.49M549.21M529.58M979.78M824.65M
Short-term Investments2.03B31.03M116.47M21.18M0
Net Receivables434.14M774.2M692.86M1.08B844.64M
Inventory2.26B3.24B3.48B3.56B3.29B
Other Current Assets131.63M80.88M1.31B78.58M100.96M
Total Current Assets5.51B4.69B6.13B5.73B5.07B
Property, Plant & Equipment (Net)3.34B4.28B4.19B4.31B4.05B
Goodwill6.23B7.01B6.8B7.4B6.83B
Intangible Assets1B2.95B1.21B2.93B2.73B
Long-term Investments2.27B1.99B451.9M528.97M592.75M
Tax Assets0174.92M0341.67M461.8M
Other Non-current Assets882.61M124.19M2.21B167.72M15.99M
Total Non-current Assets13.72B16.54B14.86B15.68B14.68B
Total Assets19.23B21.23B20.99B21.41B19.75B
Account Payables628.99M787.96M822.95M852.31M840.64M
Short-term Debt2.35B578.92M916.51M523.13M385.84M
Tax Payables015.69M084.99M0
Deferred Revenue037.83M070.87M76.97M
Other Current Liabilities119.44M381.59M108.6M81.95M459.8M
Total Current Liabilities3.47B2.02B2.33B2.16B2.02B
Long-term Debt6.94B8.15B8.99B8.42B7.39B
Deferred Tax Liabilities01.03B01.01B906.61M
Deferred Revenue (Non-current)015.12M013.94M0
Other Non-current Liabilities675.34M1.12B1.16B170.46M854.64M
Total Non-current Liabilities8.44B11.23B11.15B10.64B10.12B
Total Liabilities11.92B13.25B13.48B12.8B12.13B
Common Stock119.6M119.6M119.6M119.6M119.95M
Retained Earnings248M079.36M156.92M0
Accumulated OCI4.41B4.78B4.41B4.83B4.37B
Other Stockholders Equity00000
Minority Interest1.79B2.33B2.15B2.72B2.33B
Total Equity7.32B7.98B7.51B8.61B7.6B
Total Debt10.17B9.75B11.02B10.09B8.74B
Net Debt9.51B9.2B10.49B9.11B7.92B

Grifols, S.A.

NASDAQ:GRFS

Intrinsic Alpha fair value

Locked

Current Price

$8.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.